Patients should always seek the advice of a doctor or pharmacist in case of adverse events.
If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:
To contact us about any other issue please call:
Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.
Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:
Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:
+420 22 491 0000 nebo naše další pobočky.
World-renowned physician Dr. Paolo Biffignandi joins ELC GROUP’s Advisory Board
May 11, 2011 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today announced that former President of The Organisation for Professionals in Regulatory Affairs (TOPRA), Dr. Paolo Biffignandi MD, PhD, QPPV, FTOPRA has joined the ELC GROUP Advisory Board.
Dr. Biffignandi is a world-renowned physician, with PhDs in endocrinology and pharmacology. He is a Fellow of TOPRA, as well as an Overseas Fellow of the Royal Society of Medicine (UK).
Dr. Biffignandi brings over 30 years’ experience in Regulatory Affairs and pharmacovigilance to the company’s Advisory Board. Speaking about the appointment ELC GROUP CEO Marco Rubinstein said: “We are honoured to have Dr. Biffignandi join us and his exceptional experience and success throughout his career brings a unique perspective to our advisory board.”
ELC GROUP Business Development Manager Akhil Jain said: “We are pleased to welcome Paolo to ELC’s Advisory Board and look forward to his industry insight and contributions to ELC’s strategic plans. ELC has had the privilege to work with Dr.Biffignandi. His experience in the Regulatory Affairs space is immeasurable and his industry contributions are well noted. He is a very experienced addition to our team.”
Commenting on his appointment Dr. Biffignandi said: “ELC GROUP is the industry expert, and I’m pleased to accept this opportunity to join its Advisory Board and to contribute to its continued strategic success. I look forward to contributing to the company’s vision and sharing my experience in Regulatory Affairs.”
